Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial
暂无分享,去创建一个
P. Flamen | F. Rothé | E. Trevisi | G. Bregni | F. Sclafani | C. Senti | A. Hendlisz | Frédéric Hoerner | C. Vandeputte | E. Woff | A. Deleporte | T. Guiot | P. Gkolfakis | P. Kehagias | A. Pretta | T. Akın Telli | S. Camera | G. Critchi | Y. Wissam | S. Leduc | Elena Trevisi | Paraskevas Gkolfakis | Erwin Woff | Tuğba Akın Telli
[1] K. Spindler,et al. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] P. Flamen,et al. Combining 18F-FDG PET/CT–Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal Cancer , 2019, The Journal of Nuclear Medicine.
[3] P. Flamen,et al. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer , 2019, The Journal of Nuclear Medicine.
[4] J. Hay,et al. Cost‐effectiveness Analysis of Regorafenib and TAS‐102 in Refractory Metastatic Colorectal Cancer in the United States , 2018, Clinical colorectal cancer.
[5] J. Meyerhardt,et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial , 2017, JAMA.
[6] Daniel J Sargent,et al. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Beretta,et al. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] G. Fontanini,et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.
[9] Turgay Ayer,et al. Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Ying Cheng,et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2015, The Lancet. Oncology.
[11] Marc Peeters,et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. , 2015, The New England journal of medicine.
[12] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[13] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[14] M. Piccart,et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Michael Morse,et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Sargent,et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] W. Scheithauer,et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.